MedPacto Email Formats

Biotechnology Research • 92, Myeongdal-ro, Korea, Republic of • 21-50 Employees

MedPacto Email Formats

MedPacto uses 5 email formats. The most common is {first name}.{last name}@company.com (e.g., john.doe@company.com), used 45.6% of the time.

Format	Example	Percentage
{first name}.{last name}@company.com	john.doe@company.com	45.6%
{first name initial}{last name}@company.com	{first name initial}doe@company.com	22.3%
{first name}@company.com	john@company.com	15.1%
{first name}{last name}@company.com	johndoe@company.com	9.8%
{first name}_{last name}@company.com	john_doe@company.com	7.2%

Key Contacts at MedPacto

Minkyu Heo

Director

Bongkook Ko

Senior Director

Company overview

Headquarters	92, Myeongdal-ro, Seocho-gu, Seoul, 06668, KR
Phone number	+82269380200
Website	medpacto.com
NAICS	541714
SIC	737
Keywords	Biotechnology, Tgf-Beta, Anticancer, Vactosertib, Bio-Marker
Founded	2013
Employees	21-50
Socials

About MedPacto

MedPacto is a genome-based drug discovery and clinical-stage biotechnology company that is pursuing the development of first-in-class therapies to bring new hope to patients suffering from the most challenging diseases such as cancer. The leading drug candidate is Vactosertib, an orally bioavailable small-molecule inhibitor of the TGF-β type I receptor (TβRI) currently in phaseⅡ clinical trials with global pharmaceutical companies such as Merck and AstraZeneca. Vactosertib inhibits transforming growth factor-beta (TGF-β) pathway signaling, which is known to promote the metastasis and proliferation of cancer cells by modulating the tumor microenvironment. Vactosertib plays a synergistic role in improving the response to various therapies by inhibiting immune-suppressive TGF-β activity and suppressing the resistance mechanism of cancer stem cells. MedPacto is currently conducting combination trials with Vactosertib targeting several cancer indications including colorectal cancer, pancreatic cancer, sarcomas, NSCLC, bladder cancer, and gastric cancer. Additionally, MedPacto is currently developing MP005A, a new antibody therapeutics targeting BAG2 protein which promotes tumor formation and lung metastasis by binding the enzymes that regulate the tumor microenvironment in cancer development, and MP005D, a diagnostic kit that can detect BAG2 genes.

Employees by Management Level

Total employees: 21-50

Seniority

Employees

Manager

Entry

Senior

Employees by Department

MedPacto has 8 employees across 5 departments.

Departments

Number of employees

Funding Data

MedPacto has never raised funding before.

MedPacto Tech Stack

Discover the technologies and tools that power MedPacto's digital infrastructure, from frameworks to analytics platforms.

Sectigo

SSL/TLS certificate authorities

Nginx

Reverse proxies

Frequently asked questions

MedPacto is located in 92, Myeongdal-ro, KR.

You can reach MedPacto at +82269380200.

MedPacto was founded in 2013, making it 13 years old. The company has established itself as a significant player in its industry over this time.

MedPacto has approximately 21-50 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contacts at MedPacto

Minkyu Heo

Director

Bongkook Ko

Senior Director

4.8

40,000 users